Coronavirus Drug Discovery
Volume 1: SARS-CoV-2 (COVID-19) Prevention, Diagnosis, and Treatment
- 1st Edition - May 27, 2022
- Imprint: Elsevier
- Editor: Chukwuebuka Egbuna
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 1 5 6 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 1 7 8 - 7
Coronavirus Drug Discovery, Volume 1: SARS-CoV-2 (COVID-19) Prevention, Diagnosis, and Treatment is the first of three volumes presenting comprehensive information on drug di… Read more
Purchase options
Coronavirus Drug Discovery, Volume 1: SARS-CoV-2 (COVID-19) Prevention, Diagnosis, and Treatment is the first of three volumes presenting comprehensive information on drug discovery against COVID-19. This volume provides background information on the genesis of COVID-19, the epidemiology, transmission, pathogenesis, and mutagenesis. It also presents the various treatment options, drug discovery opportunities and vaccine developmental processes. Written by global team of experts from key institutions across the globe, this book is recommended to all concerned agencies, private research firms, and consortiums working on finding a solution to COVID-19 and its variants. By design, this book will be useful to drug developers, medicinal chemists, pharmacologists, health experts, researchers, students and faculty members in industry and academia.
- Presents information on the genesis of COVID-19, global impact and collaborative efforts
- Details the epidemiology, transmission, pathogenesis, and mutagenesis of SARS-CoV-2
- Documents the various treatment options and vaccine development for COVID-19
Researchers in organic and medicinal chemistry including drug developers, medicinal chemists, toxicologists, analytical chemists. Researchers in pharmaceutical and biotech industries
1. Antiviral drug discovery from medicinal plants2. Antiviral drug discovery from animals3. Antiviral drug discovery from marine organisms4. Antiviral drug discovery from microorganisms5. Coronavirus virology, treatment and drug discovery update6. Coronavirus outbreak: The COVID-19 episode and conspiracy theories7. Covid-19 signs and symptoms, diagnosis and prevention strategies 8. Application of computational tools for coronavirus drug discovery9. Application of nanotechnology in tackling COVID-1910. Drug discovery update for respiratory viral diseases11. Drug discovery update for gastrointestinal viral diseases12. Drug discovery update for exanthematous viral diseases13. Drug discovery update for hepatic viral diseases14. Drug discovery update for cutaneous viral diseases15. Drug discovery update for hemorrhagic viral diseases16. Drug discovery update for neurologic viral diseases17. Tools and assays in antiviral drug discovery18. Systematic review on bioactives with the most potent antiviral properties
- Edition: 1
- Published: May 27, 2022
- Imprint: Elsevier
- Language: English
CE
Chukwuebuka Egbuna
Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.
Affiliations and expertise
Africa Centre of Excellence in Public Health and Toxicological Research, University of Port Harcourt, NigeriaRead Coronavirus Drug Discovery on ScienceDirect